17 completed. 17 Phase 2, 4 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 17 |
| Phase 3 | 4 | Completed 4 |
| Phase 1 | 1 | Completed 1 |
Follow Heroin Dependence: new trials by email Literature Review of Heroin Dependence trials Research Report on Heroin Dependence
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neuroimaging and CBD for Opioid Use Disorder Cannabidiol (CBD), Placebo - Heroin Abuse, Opioid Use Disorder | Phase 2 | Completed | Yasmin Hurd | 66 | 2020-11-12 | 2025-10-27 |
| Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence Extended release morphine, Buprenorphine/Naloxone low dose, Buprenorphine/Naloxone moderate dose - Heroin Dependence, Opioid Use Disorder | Phase 1 / Phase 2 | Completed | Wayne State University | 26 | 2016-12-01 | 2020-11-10 |
| Study of Computer-Based Treatment for Drug Dependence Recovery Line Support System - Opioid-Related Disorders, Heroin Dependence | Phase 2 | Completed | Yale University | 36 | 2010-07-01 | 2020-04-02 |
| Memantine as a Supplement to Naltrexone in Treating Heroin Dependence Vivitrol, memantine - Opioid Dependence, Heroin Dependence | Phase 2 / Phase 3 | Completed | New York State Psychiatric Institute | 82 | 2008-06-01 | 2018-07-17 |
| Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial Buprenorphine - Opioid-Related Disorders, Heroin Dependence | Phase 2 / Phase 3 | Completed | New York State Psychiatric Institute | 20 | 2007-12-01 | 2019-04-24 |
| Addiction Treatment in Russia: Oral vs. Naltrexone Implant naltrexone implant, oral naltrexone, oral placebo naltrexone - Heroin Dependence, Opioid-Related Disorders | Phase 2 / Phase 3 | Completed | University of Pennsylvania | 306 | 2006-07-01 | 2019-03-18 |
| Directly Administered HIV Therapy in Methadone Clinics Directly administered antiretroviral therapy (DAART) - HIV Infections, Heroin Dependence | Phase 2 / Phase 3 | Completed | Johns Hopkins University | 107 | 2006-04-01 | 2015-04-15 |
| Naltrexone and Adrenergic Agents to Reduce Heroin Use in Heroin Addicts Naltrexone, Placebo - Heroin Dependence | Phase 2 | Completed | Baylor College of Medicine | 301 | 2006-02-01 | 2012-10-24 |
| Addition of Naltrexone to Methadone Taper Naltrexone, Placebo comparator, naltrexone - Heroin Dependence, Opioid-Related Disorders | Phase 2 | Completed | National Institute on Drug Abuse (NIDA) | 174 | 2005-04-01 | 2017-01-12 |
| Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence depot naltrexone, Compliance enhancement (CE), BNT - Opiate Dependence | Phase 2 | Completed | New York State Psychiatric Institute | 125 | 2002-06-01 | 2012-10-26 |
| Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens Levoacetyl Methadol - Heroin Dependence, Opioid-Related Disorders | Phase 2 | Completed | National Institute on Drug Abuse (NIDA) | 142 | 2001-11-01 | 2017-01-12 |
| Counseling Conditions for Buprenorphine in a Primary Care Clinic - 1 Buprenorphine - Heroin Dependence, Opioid-Related Disorders | Phase 2 | Completed | Yale University | 2000-08-01 | 2020-06-29 | |
| Opiate Dependence: Combined Naltrexone/Behavior Therapy - 1 Naltrexone, Behavioral Naltrexone Therapy (BNT), Compliance Enhancement (CE) - Heroin Dependence | Phase 2 | Completed | New York State Psychiatric Institute | 12 | 1999-08-01 | 2012-01-13 |
| The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1 LAAM - Behavior Therapy, Cocaine | Phase 2 | Completed | National Institute on Drug Abuse (NIDA) | 140 | 1997-03-01 | 2017-01-12 |
| A Laboratory Model for Heroin Abuse Medications - 8 opiates - Heroin Dependence, Opioid-Related Disorders | Phase 2 | Completed | New York State Psychiatric Institute | 8 | 1995-08-01 | 2017-07-05 |
| Treatment Efficacy for Drug Abuse and AIDS Prevention - 1 Buprenorphine - Cocaine-Related Disorders, Heroin Dependence | Phase 2 | Completed | National Institute on Drug Abuse (NIDA) | 1989-09-01 | 2017-01-12 | |
| Treatment Efficacy for Drug Abuse and AIDS Prevention - 2 Buprenorphine - Cocaine-Related Disorders, Heroin Dependence | Phase 2 | Completed | National Institute on Drug Abuse (NIDA) | 1989-09-01 | 2017-01-12 |
Opioid-Related Disorders (13) · Substance-Related Disorders (4) · Cocaine-Related Disorders (2) · HIV Infections (1) · Substance Abuse, Intravenous (1)
Chemically-Induced Disorders (17) · Mental Disorders (17) · Narcotic-Related Disorders (17) · Substance-Related Disorders (13) · Opioid-Related Disorders (4) · Blood-Borne Infections (1) · Communicable Diseases (1) · Genital Diseases (1) · Immune System Diseases (1) · Immunologic Deficiency Syndromes (1) · Infections (1) · Lentivirus Infections (1) · RNA Virus Infections (1) · Retroviridae Infections (1) · Sexually Transmitted Diseases (1)
Buprenorphine (6) · Naltrexone (4) · Methadyl Acetate (2) · Cannabidiol (1) · Fentanyl (1) · Memantine (1) · Methadone (1) · Morphine (1) · Naloxone (1) · Opiate Alkaloids (1) · Oxycodone (1) · vivitrol (1)
National Institute on Drug Abuse (NIDA) (5) · New York State Psychiatric Institute (5) · Yale University (2) · Baylor College of Medicine (1) · Johns Hopkins University (1) · University of Pennsylvania (1) · Wayne State University (1) · Yasmin Hurd (1)
United States (16) · Russia (2)
Jack Mendelson, M.D. (2) · Adam Bisaga, MD (1) · Alison Oliveto, Ph.D. (1) · Brent A. Moore, Ph.D. (1) · Edward Nunes, M.D. (1) · Edward Nunes, MD (1) · Erik W Gunderson, M.D. (1) · George Woody, MD (1) · Gregory M. Lucas, MD, PhD (1) · Herbert Kleber, M.D. (1) · John Grabowski, PhD (1) · Mark Greenwald, PhD (1) · Paolo Mannelli, M.D. (1) · Richard Schottenfeld, M.D. (1) · Thomas R. Kosten, MD (1)
PMID 16002025, PMID 16870915, PMID 17581533, PMID 17933486, PMID 19283561, PMID 20631574, PMID 21513688, PMID 21715107, PMID 22233189, PMID 23572466, PMID 23874575, PMID 27436632, PMID 40342086, PMID 40833692
R01DA010746 (2), K01DA022398 (1), K23DA020000 (1), P50DA009236 (1), R01DA009803 (1), R01DA015822 (1), R01DA017317 (1), R01DA018863 (1)